Govt Rules Propose Immediate Ban for Substandard Drugs

The Union Ministry of Health and Family Welfare has proposed strict amendments to the Drugs Rules, 1945. The new regulations will empower licensing authorities to immediately suspend the manufacturing licence of any pharmaceutical company whose products fail critical quality checks.

This policy initiative aims to eliminate contaminated or ineffective medicines from the market instantly. By holding pharmaceutical firms strictly accountable, the government seeks to safeguard public health and rebuild global trust in India's drug manufacturing ecosystem.

What Does the Government Proposal Mandate?

Under existing protocols, regulators must complete a lengthy procedure before suspending a unit. They first issue a formal show-cause notice and wait for written replies from the manufacturer.

The draft amendment introduces immediate administrative action for serious quality failures. Regulators can suspend a facility's production license as soon as laboratory tests confirm a medicine as Not of Standard Quality (NSQ). The draft rules prevent rogue firms from producing or distributing dubious batches while undergoing regulatory review.

Mandatory Root Cause Analysis and CAPA Implementation

The draft framework places a strict legal obligation on pharmaceutical companies to conduct a comprehensive Root Cause Analysis (RCA) following any quality failure.

Instead of applying superficial remedies, manufacturers must inspect their entire operational chain:

• Production Line Audits: Inspecting machinery, mixing tanks, and filtration equipment for defects.
• Raw Material Screening: Testing active pharmaceutical ingredients (APIs) and raw chemicals.
• Environmental Controls: Evaluating temperature, humidity, and storage conditions in warehouses.
• Quality Assurance Protocols: Testing internal laboratory reporting and verification standards.

Following the root-cause investigation, the company must execute effective Corrective and Preventive Action (CAPA). Corrective action resolves the immediate batch defect, while preventive action upgrades manufacturing standards so the error never recurs.

Licensing Authorities Must Approve Revocation

Under the proposed rules, a manufacturer cannot resume operations simply by promising future compliance. The local Licensing Authority must physically inspect the plant and verify the implemented CAPA steps.

The suspension remains active until government inspectors verify that the company has resolved all technical defects. If the company fails to satisfy safety inspectors, the government maintains the power to cancel the manufacturing licence permanently.

Key Benefits of the Proposed Rules

How to Submit Feedback During the Public Consultation

The Health Ministry has published the draft amendments for public and industry consultation. Stakeholders, health experts, and citizens have 30 days from the notification date to submit objections and policy recommendations.

Responses can be sent via post or email:

• Postal Address: Office of the Under Secretary (Drugs), Ministry of Health and Family Welfare, Nirman Bhawan, New Delhi.
• Official Email: drugsdiv-mohfw@gov.in